Search results: (10000)
News Bimekizumab vs. Adalimumab in the Treatment of Moderate to Severe Plaque Psoriasis
Bimekizumab is a humanized IgG1 monoclonal antibody that selectively inhibits interleukins 17A and 17F for the treatment of moderate to severe plaque psoriasis in adults for whom systemic therapy is indicated. The phase III BE SURE clinical trial focused on comparing the efficacy and safety of bimekizumab and the tumor necrosis factor-alpha (TNF-α) inhibitor adalimumab, which currently serves as one of the mainstays of systemic therapy.
News Urgent Administration of Romiplostim in Life-Threatening Bleeding Associated with ITP
Recommendations for the care of acute, especially major bleeding in individuals with severe immune thrombocytopenia (ITP) are not entirely clear. Various methods (steroid boluses, intravenous immunoglobulins, platelet transfusions, etc.) can be used to quickly increase platelet count, but the response may not always be straightforward. Recently, reports have been published regarding the use of thrombopoietin receptor agonists (TPO-RAs) specifically aimed at rapidly increasing platelet count. The use of romiplostim in patients with ITP and intracranial hemorrhage is illustrated by the following case studies.
News Consensus on the Administration of TPO-RA as Second-Line Therapy in ITP
What is the role of thrombopoietin receptor agonists (TPO-RA) in the second line treatment of patients with immune thrombocytopenia (ITP)? Italian authors conducted a survey using the Delphi method among selected experts to gather answers to this question and recommendations for clinical practice. Here, we briefly summarize the key points of their consensus published last year.
News Brentuximab vedotin in combination with lenalidomide and rituximab in R/R DLBCL – results from the open part of the ECHELON-3 study
The aim of the open run-in phase of the randomized placebo-controlled phase III ECHELON-3 study, the results of which were presented at the ASCO and EHA 2022 congresses, was to evaluate the efficacy and safety of the brentuximab vedotin/lenalidomide/rituximab (BV-len-R) triplet in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
News 6-year data from the ECHELON-1 study: How does combining brentuximab vedotin with chemotherapy affect overall survival of previously untreated cHL patients?
At this year's annual congress of the European Hematology Association (EHA), results from the analysis of 6-year data from the international randomized open-label phase III ECHELON-1 study on overall survival of patients with classical Hodgkin lymphoma (cHL) stage III/IV who received a combination of brentuximab vedotin with chemotherapy in the first-line treatment were presented, among other findings.
News Hydroresponsive Dressings for Acute and Hard-to-Heal Wounds
A recently published review of clinical evidence from nearly three dozen studies demonstrates successful debridement and cleansing of various hard-to-heal wounds using HydroClean hydroresponsive dressing, with favorable healing outcomes.
News Treatment of Depression with Persistent Severe Insomnia − Interactive Case Study
A 39-year-old patient comes to the psychiatric office due to depressive symptoms with anxiety and insomnia. He is worried about failing at work, also concerned about psychopharmaceuticals and their side effects, and is in psychotherapeutic care.
News Prophylaxis EHL products FVIII bring improvements in clinical and pharmacokinetic results
A freshly published real-world clinical practice study from Spain highlights the experience of switching patients with hemophilia A in a prophylaxis setting from standard half-life products to newer products with an extended elimination half-life.
News Time is Blood! Impact of Diagnostic Delays on Prognosis of Patients with Acquired Hemophilia A
The famous slogan of neurologists in connection with strokes – 'Time is brain!' – can be modified to 'Time is blood!' for the issue of acquired hemophilia A (AHA). The factor of time plays a crucial role in the prognosis of patients with AHA – delayed diagnosis is associated with longer administration of hemostatic treatment, higher risk of relapses, and mortality.
News Summary of New American Recommendations for Heart Failure Management
This year, the American Heart Association (AHA), the American College of Cardiology (ACC), and the Heart Failure Society of America (HFSA) released joint recommendations for the diagnosis and treatment of heart failure in clinical practice. These new guidelines replace the previous recommendations from 2013 and their 2017 update. We summarize the 10 key points to remember as outlined by the authors of the new guidelines and focus on the treatment of the subgroup of patients with heart failure with preserved ejection fraction (HFpEF).
News Full Compensation of Seizures as the Main Goal of Epilepsy Therapy: Will Patients Achieve It More Easily Than 20 Years Ago?
What is the relationship between the quality of life of patients and the degree of seizure compensation? Have the new antiepileptics (ASM) developed over the last decades improved the overall success rate of therapy?
News Prediabetes through the lens of current data and findings − and why hurry with intervention
Type 2 diabetes mellitus (DM2) is one of the most common causes of premature morbidity and mortality worldwide. The most serious impact on the health of the organism is mainly due to the macrovascular complications of this disease. However, their occurrence was often recorded before the diagnosis of DM2 was confirmed. Prediabetes itself thus represents a condition associated with the risk of developing cardiovascular (CV) complications with all their prognostic implications for patients.
News Lurasidone in Antipsychotic Therapy – A Case Study of a Virtual Patient from the Laurie Project
MUDr. Elis Bartečků, Ph.D., from the Department of Psychiatry at MU LF and FN Brno presented the current possibilities of telemedical education at the XIV congress of the Psychiatric Society of the CLS JEP in Mikulov, specifically the so-called virtual patient within the interactive online Laurie project by Angelini Pharma. The presentation involved the case of a 20-year-old man with a severe psychotic disorder and equally severe somatic comorbidity.
News Complex Impacts of Obesity on the Brains of People with Psychiatric Disorders
Obesity in individuals with bipolar disorder or schizophrenia is closely linked not only to higher mortality but also to worse progression of the psychiatric illness, lower response to psychiatric treatment, more frequent fatal outcomes (suicide), deterioration in cognitive functions, and structural brain damage. In his lecture at the XIV Congress of the Psychiatric Society of the Czech Medical Association J.E. Purkyně in Mikulov in June 2022, Professor Tomáš Hájek from Dalhousie University in Halifax, Canada, focused on these connections.